近期,石药集团宣布与阿斯利康达成战略研究合作,潜在金额将达到53亿美元;中国生物制药亦在高盛全球医疗健康年会上透露,即将完成一项具有标志性的License-out交易,显示国际市场对中国创新药资产的高度认可。 申万宏源表示,2025年上半年,多起大额BD交易落地,涉及金额高达数十亿美元,国内创新药企在全球市场中的竞争力不断增强。同时,随着FDA计划在2025年6月底前部署生成式人工智能系统并整合进...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.